BofA analyst Jason Gerberry lowered the firm’s price target on Bluebird Bio to $6 from $8 and keeps a Neutral rating on the shares. Shares were weak post the Q4 update due to a delay to lovo-cel’s BLA filing in SCD based on additional FDA info requests made in February pertaining to CMC analytical comparability, the analyst noted. While management "struck a confident tone" regarding a quick resolution and indicated that a decision is expected in coming weeks, BofA slightly reduced its view on the odds of success to 70% from 80% on increased risk to the SCD filing.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLUE:
- Bluebird Bio reaction to lovo-cel BLA delay ‘overdone,’ says Raymond James
- BLUE Turns Red on Q4 Miss and Delay in Gene Therapy Application
- Bluebird Bio reports Q4 EPS (38c), consensus (44c)
- Bluebird bio Inc (BLUE) Q4 Earnings Cheat Sheet
- Bluebird Bio options imply 10.1% move in share price post-earnings
